< Back to previous page
Researcher
Paul Clement
- Disciplines:Laboratory medicine, Palliative care and end-of-life care, Regenerative medicine, Other basic sciences, Other health sciences, Nursing, Other paramedical sciences, Other translational sciences, Other medical and health sciences
Affiliations
- Laboratory of Experimental Oncology (Division)
Member
From1 Oct 2006 → Today
Projects
1 - 7 of 7
- Evaluating the clinical utility of minimally-invasive cfDNA analysis for surveillance and early cancer detection in germline TP53 mutation carriersFrom1 Oct 2022 → TodayFunding: Foundations, funds and other with scientific goal
- Aggressive salivary gland neoplasms: institutional-international collaborative evaluation of advances in clinical management and translational research into tumor biologyFrom11 Jan 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Proof of concept: immunotherapy in glioblastoma multiforme.From21 Sep 2020 → TodayFunding: FWO fellowships
- Single cell immune profiling to improve patient stratification via liquid biopsies for cancer immunotherapyFrom1 Sep 2019 → 1 Sep 2023Funding: Foundations, funds and other with scientific goal
- Durvalumab and tremelimumab in resectable oral squamous cell carcinomaFrom1 Sep 2018 → 1 Sep 2022Funding: Own budget, for example: patrimony, inscription fees, gifts
- Determination of genetic and therapeutic dependencies of patient-derived models of brain cancerFrom1 Oct 2017 → 30 Sep 2021Funding: Fund Recuperation Fiscal Exemption
- A molecular approach to understand breast cancer cell dormancy.From1 Oct 2012 → 4 Jul 2019Funding: FWO fellowships
Publications
1 - 10 of 161
- Cellular and molecular features related to exceptional therapy response and extreme long-term survival in glioblastoma(2023)
Authors: Maxime Vanmechelen, Paul Clement, Jean-françois Daisne, Isabelle Vanden Bempt, Raf Sciot, Abhishek Garg, Patrizia Agostinis, Frederik De Smet, Steven De Vleeschouwer
Pages: 11107 - 11126 - Thrombocytopenia limits the feasibility of salvage lomustine chemotherapy in recurrent glioblastoma: a secondary analysis of EORTC 26101(2023)
Authors: Paul Clement
Pages: 13 - 22 - Cervical squamous cell carcinoma of unknown primary: Oncological outcomes and prognostic factors(2022)
Authors: Jeroen Meulemans, Sandra Nuyts, Jean-françois Daisne, Paul Clement, Annouschka Laenen, Vincent Vander Poorten
- THROMBOCYTOPENIA LIMITS THE FEASIBILITY OF SALVAGE LOMUSTINE CHEMOTHERAPY IN RECURRENT GLIOBLASTOMA: A SECONDARY ANALYSIS OF EORTC 26101(2022)
Authors: Paul Clement
Pages: 202 - 203 - Somatostatin analogues in treatment-refractory meningioma: a systematic review with meta-analysis of individual patient data(2022)
Authors: Paul Clement
Pages: 3067 - 3081 - Effectiveness of core needle biopsy in the diagnosis of thyroid lymphoma and anaplastic thyroid carcinoma: A systematic review and meta-analysis(2022)
Authors: Vincent Vander Poorten, Paul Clement
- Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial(2022)
Authors: Paul Clement
Pages: 2527 - 2535 - Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial(2022)
Authors: Paul Clement
Pages: 2440 - 2448 - Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study(2022)
Authors: Paul Clement
Pages: 2270 - 2277 - Trabectedin for recurrent WHO grade 2 or 3 meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG)(2022)
Authors: Paul Clement
Pages: 755 - 767